PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
24732660-7	2014	CONCLUSION: Our data suggest that PCMC expression of ADAM29, FLRT2, and SLC18A3 could be assessed as part of a routine screen to help identify individuals at risk of severe OSA in Asian populations.	chlorocresol	34-38	ADAM metallopeptidase domain 29	Homo sapiens	53-59
19340428-10	2009	Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies.	fludarabine	163-174	ADAM metallopeptidase domain 29	Homo sapiens	39-45
19340428-10	2009	Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies.	Cyclophosphamide	177-193	ADAM metallopeptidase domain 29	Homo sapiens	39-45